Login to Your Account

Valuations Down, But Investors Still There

Replidyne Lowers Shares, Price, Raises $45M In IPO

By Jennifer Boggs

Monday, July 10, 2006
It's a familiar story these days: Companies file for initial public offerings with high hopes but usually settle for less. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription